Hem › Burkitts lymfom › Utah
Kliniska studier för Burkitts lymfom i Utah
7 studier för Burkitts lymfom söker deltagare vid platser i Utah.
Städer i Utah
Officiell studietext (engelska)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Primary Children's Hospital, Salt Lake City
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekryterarFas 3
Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
RekryterarFas 1/2
6 Months – 25 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Primary Children's Hospital, Salt Lake City
RekryterarFas 1
Ålder 0 till 18 · Alla kön · Uppdaterad 16 sep. 2026 · NCT06173518A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Primary Children's Hospital, Salt Lake City
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Primary Children's Hospital, Salt Lake City
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Primary Children's Hospital, Salt Lake City
RekryterarFas 2
Ålder 7 till 25 · Alla kön · Uppdaterad 19 aug. 2026 · NCT05082519Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.